QBiotics to present at the 10th Annual Sachs Oncology Innovation Forum 2024 and
BIO International Convention 2024
BRISBANE, 28 May 2024.
QBiotics Group Limited (QBiotics), a clinical stage life sciences company developing novel cell signalling small molecule anticancer and wound healing pharmaceuticals is pleased to announce that Dr Victoria Gordon will present to potential partners and investors at the 10th Annual Sachs Oncology Innovation Forum 2024 and BIO International Convention 2024, both being held in the USA during May and June 2024.
Dr Gordon, QBiotics' Co-Founder and Executive Director Strategic Alliances & Investor Relations will provide an update on the Company’s oncology programme.
The 10th Annual Sachs Oncology Innovation Forum 2024 is being held at the Waldorf Astoria Chicago Hotel, Chicago, USA on 31 May 2024.
Time: 31st May at 2:20PM Central Daylight Time (CDT)
Venue: Presenting Track B
Recorded sessions will also be added to the event portal as available on demand during the virtual week, which takes place from 12 – 14 June 2024 (EDT).
The BIO International Convention takes place at the San Diego Convention Center, California, USA on
3rd - 6th June 2024.
Time: 3rd June at 4:30PM Pacific Daylight Time (PDT)
Venue: Company Presentation Theatre 1 in Hall A of the Exhibition Hall
Dr Gordon commented, “We look forward to meeting with potential partners and investors at these key conferences throughout May and June. These sorts of events provide us with the opportunity to showcase QBiotics and our pipeline of oncology and wound healing programmes, on the global stage.”
Any potential partners or investors interested in engaging around QBiotics and its programmes are invited to contact the Company directly or via the one-on-one conference partnering systems.
FURTHER INFORMATION
DR VICTORIA GORDON, EXECUTIVE DIRECTOR, STRATEGIC ALLIANCES & INVESTOR RELATIONS
communications@qbiotics.com
MEDIA ENQUIRIES / NOTES FOR EDITORS
JANE LOWE, IR DEPARTMENT
jane.lowe@irdepartment.com.au +61 411 117 774
ABOUT QBIOTICS
QBiotics is an unlisted public Australian life sciences company that specialises in the discovery and development of novel cell signalling small molecules. QBiotics applies phenotypic screening to generate breakthrough innovation in the discovery of first in class solutions to challenging medical conditions. Our current clinical focus is on novel treatments for cancer and debilitating chronic wounds.
QBiotics’ lead oncology drug, tigilanol tiglate, is a small molecule targeting a range of solid tumours and is currently in human clinical Phase II development. A veterinary formulation of tigilanol tiglate is registered and marketed as an oncology pharmaceutical, under the trade name STELFONTA®, in the USA, Europe, the UK and Australia.
QBiotics’ lead wound healing drug candidate is a small molecule targeting a range of wounds including chronic and acute wounds and burns. Preparation is in progress for a first-in-human Phase I clinical trial in patients with venous leg ulcers.